Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity

Alice Zhou, Omar Butt, Michael Ansstas, Elizabeth Mauer, Karam Khaddour, George Ansstas

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

There is a lack of effective treatments for immunotherapy-refectory melanoma. Although PARP inhibitors (PARPi) are an effective treatment strategy in cancers with homologous recombination deficiency (HRD), determining HRD status is challenging in melanoma. Here, we chart the longitudinal relationship between PARPi response and HRD scores derived from genome-wide loss of heterozygosity (LOH) in 4 patients with metastaticmelanoma. When next examining 933 melanoma cases, using an updated threshold, we observed HRD-related LOH (HRD-LOH) in nearly one-third of all cases compared with ,10% using traditional gene panels. Taken together, HRD-LOH in refractory melanoma is both a common occurrence and a potential biomarker for response to PARPi.

Original languageEnglish
Pages (from-to)688-693
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume21
Issue number7
DOIs
StatePublished - Jul 2023

Fingerprint

Dive into the research topics of 'Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity'. Together they form a unique fingerprint.

Cite this